Exservan

Drug Overview

Exservan is a specialized medication within the Neurology drug category. It is formulated to help manage Amyotrophic Lateral Sclerosis (ALS), a progressive neurodegenerative disease that affects nerve cells in the brain and spinal cord. As an oral film, Exservan was created specifically to address a major challenge for ALS patients: dysphagia, or difficulty swallowing. By dissolving directly on the tongue, it ensures patients receive this vital treatment without the risk of choking or the need for a feeding tube during the earlier stages of swallowing difficulties.

• Drug Category: Neurology
• Drug Class: Benzothiazole derivative / Neuroprotective Agent (Glutamate Inhibitor)
• Generic Name: Riluzole (oral film)
• US Brand Names: Exservan (Other riluzole forms include Rilutek, Tiglutik)
• Route of Administration: Oral (Topical on the tongue / Buccal absorption and swallowed with saliva)
• FDA Approval Status: FDA Approved

What Is It and How Does It Work? (Mechanism of Action)

Exservan acts as a neuroprotective Targeted Therapy designed to slow the damage to motor neurons. In a healthy nervous system, a chemical messenger (neurotransmitter) called glutamate helps send signals between nerve cells. However, in ALS patients, there is a buildup of too much glutamate in the brain and spinal cord. This excess glutamate overstimulates the nerve cells, leading to a toxic environment called “excitotoxicity,” which eventually destroys the motor neurons.

At the molecular level, riluzole works through a multi-step process to protect the nerves:

• Glutamate Inhibition: It blocks the release of glutamate from the nerve endings (presynaptic terminals).
• Receptor Blockade: It interferes with the binding of glutamate to its specific receptors on the next nerve cell (post-synaptic NMDA and kainate-AMPA receptors), preventing the toxic overstimulation.
• Sodium Channel Inactivation: It blocks voltage-dependent sodium channels on the nerve cell membranes. This stabilizes the electrical state of the nerve cell and further stops the release of harmful amounts of glutamate.

By reducing this toxic chemical buildup, the drug helps preserve motor neuron function for a longer period.

FDA-Approved Clinical Indications

• Primary Indication: Slowing the progression of Amyotrophic Lateral Sclerosis (ALS) and extending survival or time to tracheostomy.
• Oncological Indications: * Currently, there are no FDA-approved oncological uses for Exservan.
• Non-Oncological Indications: * Amyotrophic Lateral Sclerosis (ALS).

Dosage and Administration Protocols

Dose Adjustments and Administration Rules:

• Hepatic Insufficiency: Exservan is not recommended in patients with baseline elevated liver enzymes (transaminases greater than 5 times the upper limit of normal) or severe liver disease.
• Renal Insufficiency: No specific dosage adjustment is formally required for mild to moderate kidney disease, but caution and monitoring are advised.
• Administration: The film must be handled with dry hands. It should be placed directly on top of the tongue and allowed to dissolve completely. It should not be chewed, cut, or swallowed whole. Patients should not drink liquids to help swallow the film; it dissolves naturally with saliva.

Clinical Efficacy and Research Results

Clinical data from 2020 to 2026 continues to support riluzole as the foundational standard of care for ALS. While Exservan is a newer delivery method, its approval was based on strict bioequivalence studies proving it delivers the exact same blood plasma levels of riluzole as the traditional 50 mg tablet.

• Survival Rates: Historical and ongoing observational registries confirm that riluzole extends overall survival or delays the need for mechanical ventilation (tracheostomy) by an average of 2 to 3 months.
• Dysphagia Management: Recent clinical reviews (2022-2024) highlight that up to 80% of ALS patients develop swallowing difficulties. The oral film formulation ensures 100% medication compliance in patients who can no longer safely swallow tablets, preventing treatment interruptions.
• Combination Therapies: In recent clinical settings, riluzole is routinely and safely combined with other ALS medications (like edaravone), showing no negative chemical interaction and providing a cumulative protective effect on motor function.

Safety Profile and Side Effects

Note: Exservan (riluzole) does not carry a Black Box Warning from the FDA.

Common Side Effects (>10% of patients):

• Asthenia (Weakness): General feeling of physical weakness or lack of energy.
• Gastrointestinal Issues: Nausea, vomiting, and abdominal pain.
• Dizziness: Mild to moderate lightheadedness.
• Decreased Lung Function: Subtle changes in respiratory capacity.
• Oral Numbness: Specifically with the oral film, mild tingling or numbness on the tongue may occur temporarily after administration.

Serious Adverse Events:

• Hepatic Injury: Severe liver damage and elevated liver enzymes (ALT/AST).
• Neutropenia: A dangerous drop in white blood cells, increasing the risk of infections.
• Interstitial Lung Disease: Inflammation and scarring of the lung tissue.

Management Strategies:

• If a patient develops a fever or signs of respiratory infection, an immediate complete blood count (CBC) must be drawn to check for neutropenia.
• If liver enzymes (ALT) rise to greater than 5 times the upper limit of normal, the physician should discontinue the drug immediately.
• If a patient develops a dry cough or difficulty breathing not related to ALS progression, chest imaging is required to rule out interstitial lung disease.

Connection to Stem Cell and Regenerative Medicine (If Applicable)

As ALS represents a severe loss of central nervous system tissue, current global research heavily focuses on combining foundational drugs like riluzole with advanced regenerative therapies. In numerous clinical trials (2020-2026) investigating Mesenchymal Stem Cells (MSCs) and neural progenitor cell infusions for ALS, riluzole acts as the mandatory baseline therapy. Researchers are studying whether the neuroprotective environment created by riluzole (by clearing toxic glutamate) increases the survival, engraftment, and growth-factor secretion of newly introduced stem cells. By calming the “toxic storm” in the spinal cord, Exservan may act as a crucial biological bridge that helps regenerative cellular therapies work more effectively.

Patient Management and Practical Recommendations

Pre-treatment Tests:

• Liver Function Tests (LFTs): Baseline serum aminotransferases (ALT, AST), bilirubin, and GGT must be drawn before the first dose.
• Complete Blood Count (CBC): To establish a baseline white blood cell count.

Precautions During Treatment:

• Monitor liver enzymes (ALT) every month for the first 3 months of treatment, then every 3 months for the remainder of the first year, and periodically thereafter.
• Patients should be advised to monitor for unexplained fevers, chills, or severe fatigue, which could indicate a drop in white blood cells.

Do’s and Don’ts:

• DO handle the oral film with completely dry hands to prevent it from dissolving on your fingers.
• DO take the medication strictly on an empty stomach (1 hour before or 2 hours after meals) to ensure full absorption.
• DON’T drink water or other liquids while the film is dissolving on the tongue.
• DON’T consume heavy amounts of alcohol, as it drastically increases the risk of severe liver damage when combined with this medication.
• DON’T stop taking the medication without consulting your neurologist, even if you do not feel immediate physical improvement (the drug works to slow future damage, not reverse past damage).

Legal Disclaimer

The information provided in this guide is for educational and informational purposes only and does not constitute medical advice. It is not intended to be a substitute for professional medical diagnosis, treatment, or clinical judgment. Always seek the advice of a qualified healthcare provider with any questions you may have regarding a medical condition or medication. Never disregard professional medical advice or delay in seeking it because of something you have read in this material